Body CompositionGLOWNCT07422987
GLP-1RA Effects on Lean Mass and Bone Health in Midlife Women
An observational study of Body Composition and Muscle Function, run by University of Kansas Medical Center at 1 site in United States.
Trial summary
This study is designed with the interest to learn on the effects of estrogen levels and how it affects body compositions and muscle function in midlife women who are taking a GLP-1RA for weight loss. Read more about this study
- Who is it for?
- Ages 35 to 60 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Body Composition, Muscle Function, GLP-1
- How many people
- 50 participants
- Where
- 1 siteUnited States
- Study dates
- 12 Feb 2026to 30 Jun 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 35 to 60 years
- Women only
- Healthy volunteers accepted
- Adult
Study population: Women in midlife who are establishing care at the KU OBGYN's weight management clinic
Who may be able to join
- Females
- Age 35-60 year
- BMI≥30 or BMI≥27 and at least one cardiometabolic risk factor (dyslipidemia, hypertension, obstructive sleep apnea, metabolic syndrome, fatty liver, PCOS)
- Newly prescribed a GLP-1RA medication
- English speaking
- Body weight stable for the past 6 months
Who cannot join
- Pregnant women
- Under age 35 or over age 60
- Born male
- Cannot consent for themselves
- Cannot read and speak in English
- Type 2 diabetes
Show all 9Show fewer
- Recently discontinued a GLP-1RA medication (less than 6-months since discontinuing)
- Contraindications for taking a GLP-1 RA medication (personal or family history of medullary thyroid carcinoma, personal or family history of multiple endocrine neoplasia type 2, personal history of pancreatitis, pregnancy, hypersensitivity to the drug or any component of the drug, active suicidal ideation)
- Currently taking aromatase inhibitors or selective estrogen receptor modulators (SERMs)
Trial locations and contacts
1 site in 1 country.
United States1 site
The University of Kansas Medical Center
Kansas City, Kansas, 66160
About this study
This study is designed with the interest to learn on the effects of estrogen levels and how it affects body compositions and muscle function in midlife women who are taking a GLP-1RA for weight loss.
- Conditions
- Body Composition, Muscle Function, GLP-1, Estrogen Level
- Keywords
- Midlife, Women's health, Dietary quality
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| GLOW Participants | New patients, those who are newly prescribed a GLP-1RA medication will be invited to participate in the study where different measurements will be completed to assess body composition, hormone levels, muscle strength and nutrition. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Body weight
Assess changes in body weight by measuring weight on a calibrated scale
Measured: Baseline through 6-month visit
Body composition
Assess changes in lean and fat mass and fat-free mass in kilograms by total body DXA scan
Measured: Baseline through 6-month visit
Bone mineral density (BMD)
Assess changes in bone mineral density (BMD) by completing femur DXA scans
Measured: Baseline through 6-month visit
Muscle function
Assess muscle function changes in pounds by completing Grip strength tests
Measured: Baseline through 6-month visit
Muscle function
Assess changes to muscle function by the number of repetitions achieved per 30-second Sit-to-stand test
Measured: Baseline through 6-month visit
Secondary outcomes (4)
Estrogen level role in BMD changes during GLP-1RA therapy
Examine the moderating role of estrogen levels on changes in bone mineral density (BMD) during GLP-1RA therapy.
Measured: Baseline through 6-month visit
Estrogen level role in muscle function changes during GLP-1RA therapy
Examine the moderating role of estrogen levels on changes in muscle function during GLP-1RA therapy.
Measured: Baseline through 6-month visit
Diet intake
Examine changes in dietary intake including protein consumption by collecting 24-hrs diet recalls.
Measured: Baseline through 6-month visit
Diet quality
Examine changes in dietary quality by collecting 24-hrs diet recalls.
Measured: Baseline through 6-month visit
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Feb 2026
- Study start12 Feb 2026
- Primary completion30 Jun 2027 (estimated)
- Study completion30 Jun 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Body CompositionStudies of the same condition, open and under way.
- More trials run by University of Kansas Medical CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Kansas Medical Center
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Johanna Finkle, MD, Principal investigator, University of Kansas Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07422987
- Sponsor's protocol ID
- STUDY00161780
- Acronym
- GLOW
- Status last verified
- Aug 2026
- First submitted
- 26 Jan 2026
- Last updated
- 7 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 7 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- GLP-1RA Effects on Lean Mass and Bone Health in Midlife Women
- ClinicalTrials.gov ID
- NCT07422987
- Acronym / sponsor ID
- GLOW / STUDY00161780
- Conditions
- Body Composition, Muscle Function, GLP-1, Estrogen Level
- Keywords
- Midlife, Women's health, Dietary quality
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- University of Kansas Medical CenterUniversity, hospital or other
- Study start
- 12 Feb 2026 (actual)
- Primary completion
- 30 Jun 2027 (estimated)
- Study completion
- 30 Jun 2027 (estimated)
- First posted
- 20 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is designed with the interest to learn on the effects of estrogen levels and how it affects body compositions and muscle function in midlife women who are taking a GLP-1RA for weight loss.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| GLOW Participants | – | –New patients, those who are newly prescribed a GLP-1RA medication will be invited to participate in the study where different measurements will be completed to assess body composition, hormone levels, muscle strength and nutrition. |
Who may qualify
- Ages
- 35 to 60 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult
- Study population
- Women in midlife who are establishing care at the KU OBGYN's weight management clinic
Key inclusion criteria (6 listed)
- Females
- Age 35-60 year
- BMI≥30 or BMI≥27 and at least one cardiometabolic risk factor (dyslipidemia, hypertension, obstructive sleep apnea, metabolic syndrome, fatty liver, PCOS)
- Newly prescribed a GLP-1RA medication
- English speaking
Key exclusion criteria (9 listed)
- Pregnant women
- Under age 35 or over age 60
- Born male
- Cannot consent for themselves
- Cannot read and speak in English
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Body weight
Time frame: Baseline through 6-month visit
Assess changes in body weight by measuring weight on a calibrated scale
Body composition
Time frame: Baseline through 6-month visit
Assess changes in lean and fat mass and fat-free mass in kilograms by total body DXA scan
Bone mineral density (BMD)
Time frame: Baseline through 6-month visit
Assess changes in bone mineral density (BMD) by completing femur DXA scans
Muscle function
Time frame: Baseline through 6-month visit
Assess muscle function changes in pounds by completing Grip strength tests
Muscle function
Time frame: Baseline through 6-month visit
Assess changes to muscle function by the number of repetitions achieved per 30-second Sit-to-stand test
4 secondary outcomes
Estrogen level role in BMD changes during GLP-1RA therapy
Time frame: Baseline through 6-month visit
Estrogen level role in muscle function changes during GLP-1RA therapy
Time frame: Baseline through 6-month visit
Diet intake
Time frame: Baseline through 6-month visit
Diet quality
Time frame: Baseline through 6-month visit
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Aug 2026.
Related trials for Body Composition
Not yet recruitingObservational study
Evaluating Metabolic Health in Individuals With Extreme Obesity
BMI>40
Active, not recruitingObservational study
Practical Geriatric Assessment (PGA) Implementation Strategies and Correlative Evaluations (PACE-70)
Geriatric Assessment, Advanced Cancer
Recruiting
Dietary Intervention Study on Liver Health in Young Adults
Liver Health
RecruitingObservational study
Growing Little PEAPODS Study
Premature Birth, Premature Infant
RecruitingObservational study
Multimodal Assessment of Sarcopenia Using Shear Wave Elastography, Dual-Energy X-ray Absorptiometry, Bioelectrical Impedance Analysis, and Physical Performance Measures
Sacropenia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Johanna Finkle, MD principal investigator
University of Kansas Medical Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Body Composition and Muscle Function, run by University of Kansas Medical Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 7 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Body weight (time frame: Baseline through 6-month visit). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Aug 2026.